Online event ‘The Life Sciences Paradox’
Innovation is crucial, yet regulatory restrictions, slow market adoption, budget cuts and increased competition are putting immense pressure on the medical companies’ investment choices. They need to face the paradox. Will you stay focused on current product lines, technologies and methodologies? Or will you put more emphasis on solving longer-term challenges in preventative, personalized and value-based healthcare?
Join us for the Life Sciences Paradox event on September 22nd together with MedTech Partners, imec and Cochlear. In 4 sessions, we’ll cover different facets of this paradox, tackling reimbursement, R&D strategies, digital innovation and clinical trials.
Thursday 22 September
10:00 to 12:15 CEST
in Life Sciences
Discover the program
10h00: The reimbursement paradox
Should you add reimbursement to your business plan?
Boris Polm, Program Manager at MedtechPartners
Frans van Andel, Senior Specialist in Reimbursement of Health Technologies and Public Health at Seijgraaf
Many healthcare start-ups see getting their innovation reimbursed as the ultimate goal. However, the regulations can be unclear or insufficient. We often hear that there’s no clear pathway from innovative (digital) care to reimbursed healthcare. In this session, we’ll shed light on this reimbursement paradox influencing your innovation strategy. Who are the main decision makers? What’s a typical path towards reimbursement under the national health insurance scheme? What’s needed when it comes to clinical data? And what are the big differences between the Dutch and Belgian health insurers?
10h35: The R&D paradox
Do you innovate your product based on technology push or market pull?
Nick van Helleputte, Scientific Director Circuits & Systems for Health at imec
Dirck Seynaeve, Project Coordinator IoT at Verhaert
Innovation often starts with research into the possibilities of new technologies. When should you stop exploring technology and switch to a markets and user-focused approach? What happens when you make that turn too late, too early, or don’t even make it? How do you switch, incorporate market adoption and window of opportunity? Get insights from Verhaert Masters in Innovation and imec on the paradox between technology push and market pull.
11h10: The digital paradox
Should you digitize your company processes or your product?
Ornella Torres Melkebeek, Consultant DesignLab at Verhaert
Wouter Hendrickx, Manager Innovation Acceleration Solutions – Smart Life Sciences at Verhaert
Increased competition puts immense pressure on companies in the life sciences sector. Adding a digital layer helps you differentiate your product and stay ahead of competitors. On a product level, it’ll add new product competences and development methods. On a company level, IoT devices improve service, maintenance, app development, electronics manufacturing and subscription-based business models. How do you balance investment between both? During this session, Verhaert will discuss this paradox using the example of the rehab market.
11h40: The user insights paradox
Do you invest in an app for clinical trials or user experience?
Tom Bertens, Director Research Algorithms & Applications at Cochlear
Laurent Schauvliege, Manager Innovation Acceleration at Verhaert Digital Innovation
Every Life Sciences event discusses digitilization. How do you choose between investing in digitizing new products for customers and developing digital solutions for effective and innovative clinical trials? A completely different objective, different users, and different insights. That’s not all. Potential revenues differ significantly and the risk isn’t comparable. Is creating a specific application to gain user insights in trials even worth the money? In this session with Cochlear, we’ll give you some inspiration on how to tackle this paradox.
Meet your hosts
Meet your speakers
Let’s resolve the Life Sciences paradox together!
The webinar took place on September 22nd, stay tuned for the recordings.